MTST (MetaStat) ROE % Adjusted to Book Value: 0.00% (As of Feb. 2018)


What is MetaStat ROE % Adjusted to Book Value?

MetaStat MTST ROE % Adjusted to Book Value is 0.00% as of Feb. 2018.

MetaStat's ROE % for the quarter that ended in Feb. 2018 was 0.00%. MetaStat's PB Ratio for the quarter that ended in Feb. 2018 was N/A. MetaStat's ROE % Adjusted to Book Value for the quarter that ended in Feb. 2018 was N/A.

MetaStat ROE % Adjusted to Book Value Related Terms

MetaStat ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for MetaStat's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MetaStat ROE % Adjusted to Book Value Chart

MetaStat Annual Data
Trend Feb09 Feb10 Feb11 Feb12 Feb13 Feb14 Feb15 Feb16 Feb17 Feb18
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

MetaStat Quarterly Data
May13 Aug13 Nov13 Feb14 May14 Aug14 Nov14 Feb15 May15 Aug15 Nov15 Feb16 May16 Aug16 Nov16 Feb17 May17 Aug17 Nov17 Feb18
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Negative Equity 0.00 0.00 0.00 0.00

MTST vs OBMP, NSPX, ATRX: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, MetaStat's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MetaStat ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MetaStat's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where MetaStat's ROE % Adjusted to Book Value falls into.


MetaStat ROE % Adjusted to Book Value Calculation

MetaStat's ROE % Adjusted to Book Value for the fiscal year that ended in Feb. 2018 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / N/A
=N/A

MetaStat's ROE % Adjusted to Book Value for the quarter that ended in Feb. 2018 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / N/A
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of 0.00% mean?
MetaStat (MTST) has a ROE % Adjusted to Book Value of 0.00% as of Feb. 2018. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on MetaStat and its competitors.
Is MetaStat's ROE % Adjusted to Book Value too high?
MetaStat's current ROE % Adjusted to Book Value is 0.00%.
How does MetaStat's ROE % Adjusted to Book Value compare to OBMP and NSPX?
MetaStat's ROE % Adjusted to Book Value of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on MetaStat and its competitors. MetaStat's current ROE % Adjusted to Book Value is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MetaStat stock overvalued right now?
MetaStat (MTST) has a current ROE % Adjusted to Book Value of 0.00%. The current ROE % Adjusted to Book Value is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For MetaStat (MTST), the current ROE % Adjusted to Book Value is 0.00% as of Feb. 2018. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MetaStat Business Description

Address 27 Drydock Avenue, 2nd Floor, Boston, MA, USA, 02210
MetaStat Inc is a us-based biotechnology company which focuses on discovering and developing personalized therapeutic (Rx) and diagnostic (Dx) treatment solutions for cancer patients. The company focuses on development programs of the novel therapeutic product candidates that target the Mena protein isoform whereas the Companion Diagnostics program is focused on developing companion tests to be used in combination with cancer drugs, that provide essential information for the safe and effective use of a corresponding drug or biological product to improve patient outcome. It also develops a prognostic diagnostic program which is focused on developing diagnostic tests that predict the risk of future metastasis in cancer patients following the initial treatment of their primary tumor.